Update shared on22 Aug 2025
Fair value Increased 16%Sleep Cycle’s consensus price target has been revised upward, driven primarily by an increase in its future P/E multiple and a modest improvement in net profit margin, resulting in a new fair value estimate of SEK44.75.
What's in the News
- Launched in-app promotion platform in collaboration with HelloFresh, Factor, and YouFoodz, enabling external brands to target Sleep Cycle’s user base with curated wellness offers and supporting expansion of partnership programs.
- Initiated a clinical study to validate a new smartphone-based feature for screening and monitoring obstructive sleep apnea without additional hardware, aiming to provide a scalable, cost-efficient solution for early detection, led by experts in sleep science and AI.
Valuation Changes
Summary of Valuation Changes for Sleep Cycle
- The Consensus Analyst Price Target has significantly risen from SEK38.50 to SEK44.75.
- The Future P/E for Sleep Cycle has significantly risen from 12.31x to 13.70x.
- The Net Profit Margin for Sleep Cycle has risen slightly from 19.39% to 20.00%.
Disclaimer
AnalystConsensusTarget is a tool utilizing a Large Language Model (LLM) that ingests data on consensus price targets, forecasted revenue and earnings figures, as well as the transcripts of earnings calls to produce qualitative analysis. The narratives produced by AnalystConsensusTarget are general in nature and are based solely on analyst data and publicly-available material published by the respective companies. These scenarios are not indicative of the company's future performance and are exploratory in nature. Simply Wall St has no position in the company(s) mentioned. Simply Wall St may provide the securities issuer or related entities with website advertising services for a fee, on an arm's length basis. These relationships have no impact on the way we conduct our business, the content we host, or how our content is served to users. The price targets and estimates used are consensus data, and do not constitute a recommendation to buy or sell any stock, and they do not take account of your objectives, or your financial situation. Note that AnalystConsensusTarget's analysis may not factor in the latest price-sensitive company announcements or qualitative material.